Janux Therapeutics JANX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $51.83M-29.7% | $52.33M-87.8% | $48.39M+80.9% | $52.45M+258% | $73.74M-65.3% | ||
| $904.56M-3.8% | $914.23M+53.8% | $940.6M+49.0% | $943.57M+49.4% | $940.4M+114% | ||
| $816K0.0% | $816K0.0% | $816K0.0% | $816K0.0% | $816K0.0% | ||
| —— | —— | —— | —— | —— | ||
| $38.62M+13.2% | $37.15M+18.6% | $36.32M+29.6% | $35.52M+40.8% | $34.12M+47.8% | ||
| $1B-2.1% | $975.89M-5.6% | $998.09M+49.8% | $1.01B+51.9% | $1.02B+55.4% | ||
| $3.55M-28.3% | $3.85M-20.8% | $4.31M-19.7% | $4.69M-21.1% | $4.95M-24.1% | ||
| $17.87M-5.3% | $18.4M-4.6% | $18.92M-3.9% | $18.46M-8.0% | $18.88M-7.7% | ||
| $3.94M+41.3% | $2.61M-9.6% | $2.63M-6.9% | $2.69M+2.0% | $2.79M+10.6% | ||
| $1.03B-2.1% | $1B-5.6% | $1.02B+47.4% | $1.03B+49.3% | $1.05B+52.5% | ||
| $15.22M+50.8% | $14.19M+42.0% | $13.25M+57.9% | $12.32M+46.0% | $10.09M+11.0% | ||
| $15.48M+16.0% | $17.63M+50.9% | $22.16M+70.1% | $16.03M+87.1% | $13.34M+130% | ||
| —— | —— | —— | —— | —— | ||
| $2.47M+36.5% | $2.39M+36.8% | $2.28M+35.0% | $1.87M+14.9% | $1.81M+15.1% | ||
| —— | —— | —— | —— | —— | ||
| $58.92M+237% | $25M+43.2% | $27.83M+62.1% | $21.38M+85.2% | $17.5M+65.0% | ||
| $19.1M-8.2% | $19.75M-7.2% | $20.38M-6.3% | $20.32M-8.4% | $20.8M-8.0% | ||
| $21.57M-4.6% | $22.14M-3.8% | $22.66M-3.3% | $22.19M-6.8% | $22.61M-6.5% | ||
| $86.69M+126% | $44.74M+15.5% | $48.21M+23.9% | $41.7M+23.6% | $38.3M+15.3% | ||
| —— | —— | —— | —— | —— | ||
| $60K+1.7% | $60K+1.7% | $60K+15.4% | $59K+13.5% | $59K+15.7% | ||
| $1.32B+3.7% | $1.3B+3.6% | $1.29B+49.2% | $1.28B+51.0% | $1.27B+51.2% | ||
| -$375.74M-43.8% | -$351.38M-47.8% | -$319.44M-46.8% | -$295.12M-55.8% | -$261.27M-42.4% | ||
| $576K-84.7% | $4.32M+99.5% | $4.56M-41.7% | $3.75M+332% | $3.76M+817% | ||
| $941.54M-7.0% | $956.82M-6.4% | $976.56M+48.8% | $990.52M+50.6% | $1.01B+54.4% | ||
| $1.03B-2.1% | $1B-5.6% | $1.02B+47.4% | $1.03B+49.3% | $1.05B+52.5% | ||
| $3.94M+41.3% | $2.61M-9.6% | $2.63M-6.9% | $2.69M+2.0% | $2.79M+10.6% | ||
| $17.87M-5.3% | $18.4M-4.6% | $18.92M-3.9% | $18.46M-8.0% | $18.88M-7.7% | ||
| $17.87M-5.3% | $18.4M-4.6% | $18.92M-3.9% | $18.46M-8.0% | $18.88M-7.7% | ||
| $3.94M+41.3% | $2.61M-9.6% | $2.63M-6.9% | $2.69M+2.0% | $2.79M+10.6% | ||
| $904.56M-3.8% | $914.23M+53.8% | $940.6M+49.0% | $943.57M+49.4% | $940.4M+114% | ||
| $17.87M-5.3% | $18.4M-4.6% | $18.92M-3.9% | $18.46M-8.0% | $18.88M-7.7% | ||
| $3.94M+41.3% | $2.61M-9.6% | $2.63M-6.9% | $2.69M+2.0% | $2.79M+10.6% | ||
| —— | —— | —— | —— | —— | ||
| $15.48M+16.0% | $17.63M+50.9% | $22.16M+70.1% | $16.03M+87.1% | $13.34M+130% | ||
| $15.48M+16.0% | $17.63M+50.9% | $22.16M+70.1% | $16.03M+87.1% | $13.34M+130% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $21.57M-4.6% | $22.14M-3.8% | $22.66M-3.3% | $22.19M-6.8% | $22.61M-6.5% | ||
| $1.32B+3.7% | $1.3B+3.6% | $1.29B+49.2% | $1.28B+51.0% | $1.27B+51.2% | ||
| $60K+1.7% | $60K+1.7% | $60K+15.4% | $59K+13.5% | $59K+15.7% | ||
| —— | —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Janux Therapeutics's total assets?
- Janux Therapeutics (JANX) holds $1.0B in total assets, down 2.1% year over year.
- How much debt does Janux Therapeutics have?
- Janux Therapeutics carries $21.6M in total debt against $941.5M of shareholders' equity, a debt-to-equity ratio of 0.02.
- How much cash does Janux Therapeutics have?
- Janux Therapeutics holds $51.8M in cash and equivalents.
- Can Janux Therapeutics cover its short-term obligations?
- Its current ratio is 17.01 — current assets exceed current liabilities.
- Where does Janux Therapeutics's balance sheet data come from?
- Every line is extracted from Janux Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
